Next-Generation Tissue Factor–Targeting ADC XB002 to be Examined in Several Solid Tumors
May 12th 2021
The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the novel agent XB002 is set to be examined in an upcoming phase 1 clinical trial that is expected to begin the second quarter of 2021.